Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 16/20 | 0.56 |
| ▸ | JAK2 | O60674 | 11/20 | 0.53 |
| ▸ | JAK1 | P23458 | 11/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342554 | 0.86 | ATR (0.46) | SYKCYP2C9JAK3JAK2ATR | |
| SCHEMBL2275187 | 0.86 | ATR (0.48) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2282968 | 0.85 | SYK (0.63) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2282223 | 0.82 | SYK (0.64) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL14655300 | 0.82 | SYK (0.59) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2277345 | 0.82 | SYK (0.59) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2282301 | 0.81 | SYK (0.63) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2277240 | 0.81 | SYK (0.69) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2282410 | 0.80 | JAK3 (0.65) | SYKCYP2C9JAK3JAK2JAK1 | |
| SCHEMBL2275385 | 0.80 | SYK (0.55) | SYKCYP2C9JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | claimed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | claimed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | SYK 1/4885CYP2C9 3511/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.